---
input_text: 'Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome:
  a randomised, double-blind, placebo-controlled trial. BACKGROUND: Dravet syndrome
  is a rare, treatment-resistant developmental epileptic encephalopathy characterised
  by multiple types of frequent, disabling seizures. Fenfluramine has been reported
  to have antiseizure activity in observational studies of photosensitive epilepsy
  and Dravet syndrome. The aim of the present study was to assess the efficacy and
  safety of fenfluramine in patients with Dravet syndrome. METHODS: In this randomised,
  double-blind, placebo-controlled clinical trial, we enrolled children and young
  adults with Dravet syndrome. After a 6-week observation period to establish baseline
  monthly convulsive seizure frequency (MCSF; convulsive seizures were defined as
  hemiclonic, tonic, clonic, tonic-atonic, generalised tonic-clonic, and focal with
  clearly observable motor signs), patients were randomly assigned through an interactive
  web response system in a 1:1:1 ratio to placebo, fenfluramine 0 2 mg/kg per day,
  or fenfluramine 0 7 mg/kg per day, added to existing antiepileptic agents for 14
  weeks. The primary outcome was the change in mean monthly frequency of convulsive
  seizures during the treatment period compared with baseline in the 0 7 mg/kg per
  day group versus placebo; 0 2 mg/kg per day versus placebo was assessed as a key
  secondary outcome. Analysis was by modified intention to treat. Safety analyses
  included all participants who received at least one dose of study medication. This
  trial is registered with ClinicalTrials.gov with two identical protocols NCT02682927
  and NCT02826863. FINDINGS: Between Jan 15, 2016, and Aug 14, 2017, we assessed 173
  patients, of whom 119 patients (mean age 9 0 years, 64 [54%] male) were randomly
  assigned to receive either fenfluramine 0 2 mg/kg per day (39), fenfluramine 0 7
  mg/kg per day (40) or placebo (40). During treatment, the median reduction in seizure
  frequency was 74 9% in the fenfluramine 0 7 mg/kg group (from median 20 7 seizures
  per 28 days to 4 7 seizures per 28 days), 42 3% in the fenfluramine 0 2 mg/kg group
  (from median 17 5 seizures per 28 days to 12 6 per 28 days), and 19 2% in the placebo
  group (from median 27 3 per 28 days to 22 0 per 28 days). The study met its primary
  efficacy endpoint, with fenfluramine 0 7 mg/kg per day showing a 62 3% greater reduction
  in mean MCSF compared with placebo (95% CI 47 7-72 8, p<0 0001); fenfluramine 0
  2 mg/kg per day showed a 32 4% reduction in mean MCSF compared with placebo (95%
  CI 6 2-52 3, p=0 0209). The most common adverse events (occurring in at least 10%
  of patients and more frequently in the fenfluramine groups) were decreased appetite,
  diarrhoea, fatigue, lethargy, somnolence, and decreased weight. Echocardiographic
  examinations revealed valve function within the normal physiological range in all
  patients during the trial and no signs of pulmonary arterial hypertension. INTERPRETATION:
  In Dravet syndrome, fenfluramine provided significantly greater reduction in convulsive
  seizure frequency compared with placebo and was generally well tolerated, with no
  observed valvular heart disease or pulmonary arterial hypertension. Fenfluramine
  could be an important new treatment option for patients with Dravet syndrome. FUNDING:
  Zogenix.'
raw_completion_output: |-
  primary_disease: Dravet syndrome
  medical_actions: randomized double-blind placebo-controlled trial; enrolled children and young adults; 6-week observation period; randomly assigned to placebo or fenfluramine 0.2 mg/kg per day or fenfluramine 0.7 mg/kg per day; added to existing antiepileptic agents for 14 weeks; safety analyses; echocardiographic examinations
  symptoms: seizures; frequent, disabling seizures; convulsive seizures; hemiclonic; tonic; clonic; tonic-atonic; generalized tonic-clonic; focal with clearly observable motor signs
  chemicals: Fenfluramine hydrochloride; fenfluramine
  action_annotation_relationships: randomized double-blind placebo-controlled trial TREATS seizures IN Dravet syndrome; fenfluramine TREATS frequent, disabling seizures IN Dravet syndrome; fenfluramine 0.2 mg/kg per day (with Fenfluramine hydrochloride) TREATS convulsive seizures IN Dravet syndrome; fenfluramine 0.7 mg/kg per day (with Fenfluramine hydrochloride) TREATS convulsive seizures IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS hemiclonic IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS tonic IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS clonic IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS tonic-atonic IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS generalized tonic-clonic IN Dravet syndrome; fenfluramine (with Fenfluramine hydrochloride) TREATS focal with clearly observable motor signs IN Dravet syndrome
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  fenfluramine (with Fenfluramine hydrochloride) TREATS focal with clearly observable motor signs IN Dravet syndrome

  ===

extracted_object:
  primary_disease: MONDO:0100135
  medical_actions:
    - randomized double-blind placebo-controlled trial
    - enrolled children and young adults
    - 6-week observation period
    - randomly assigned to placebo or fenfluramine 0.2 mg/kg per day or fenfluramine
      0.7 mg/kg per day
    - added to existing antiepileptic agents for 14 weeks
    - safety analyses
    - echocardiographic examinations
  symptoms:
    - HP:0001250
    - frequent, disabling seizures
    - convulsive seizures
    - hemiclonic
    - tonic
    - clonic
    - tonic-atonic
    - generalized tonic-clonic
    - focal with clearly observable motor signs
  chemicals:
    - CHEBI:59729
    - CHEBI:5000
  action_annotation_relationships:
    - subject: <randomized double-blind placebo-controlled trial>
      predicate: <TREATS>
      object: <seizures>
      qualifier: <Dravet syndrome>
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - predicate: TREATS
      object: frequent, disabling seizures
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: fenfluramine 0.2 mg/kg per day (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: convulsive seizures
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: fenfluramine 0.7 mg/kg per day
      predicate: TREATS
      object: convulsive seizures
      qualifier: MONDO:0100135
      subject_qualifier: with Fenfluramine hydrochloride
      subject_extension: CHEBI:5000
    - subject: fenfluramine (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: hemiclonic
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: fenfluramine (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: tonic
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: fenfluramine (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: clonic
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: fenfluramine (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: tonic-atonic seizures
      qualifier: MONDO:0100135
      subject_extension: CHEBI:5000
    - subject: Fenfluramine hydrochloride treatment
      predicate: TREATS
      object: HP:0002069
      qualifier: MONDO:0100135
      subject_qualifier: with
      subject_extension: CHEBI:5000
      object_extension: generalized tonic-clonic
    - subject: fenfluramine (with Fenfluramine hydrochloride)
      predicate: TREATS
      object: HP:0030650
      qualifier: MONDO:0100135
      object_qualifier: with clearly observable motor signs
      subject_extension: CHEBI:5000
      object_extension: clearly observable motor signs
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
  - id: MAXO:0000943
    label: deep brain stimulation (DBS)
  - id: MAXO:0000940
    label: responsive neurostimulation (RNS)
  - id: MONDO:0005071
    label: Neurological disorders
  - id: CHEBI:133053
    label: 7-OH-CBD
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: HP:0001873
    label: thrombocytopenia
  - id: CHEBI:8107
    label: Phenytoin
  - id: HP:0012758
    label: Neurodevelopmental delays
  - id: HP:0011951
    label: Aspiration pneumonia
  - id: CHEBI:71013
    label: Perampanel
  - id: CHEBI:63004
    label: Sodium bromide
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0000718
    label: Aggression
  - id: HP:0031475
    label: nonconvulsive status epilepticus
  - id: HP:0001609
    label: hoarseness
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0002446
    label: astrogliosis
  - id: CHEBI:9948
    label: verapamil
  - id: CHEBI:52140
    label: clemizole
  - id: CHEBI:3387
    label: Carbamazepine
  - id: CHEBI:40594
    label: AEDs
  - id: CHEBI:68478
    label: Everolimus
  - id: HP:6000040
    label: Neuropathic pain
  - id: CHEBI:65353
    label: lorcaserin
  - id: MAXO:0000016
    label: Cell therapies
  - id: HP:0001699
    label: Sudden death
  - id: CHEBI:59729
    label: Fenfluramine hydrochloride
  - id: HP:0030650
    label: focal
